

Emmanuel Raffoux

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9060395/publications.pdf>

Version: 2024-02-01

57
papers

1,348
citations

430874

18
h-index

345221

36
g-index

57
all docs

57
docs citations

57
times ranked

2041
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatosplenic Candidiasis in Patients With Hematological Malignancies: A 13-Year Retrospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac088.	0.9	4
2	Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 1365-1372.	2.4	3
3	Blinatumomab+â€œponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. <i>Leukemia and Lymphoma</i> , 2021, 62, 620-629.	1.3	36
4	Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. <i>Blood Advances</i> , 2021, 5, 176-184.	5.2	56
5	Characteristics and mid-term follow-up of COVID-19 patients with hematological diseases: a retrospective study from a French tertiary care hospital. <i>Blood Cancer Journal</i> , 2021, 11, 129.	6.2	0
6	Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use. <i>Haematologica</i> , 2021, 106, 1767-1769.	3.5	8
7	Early detection of <i>WT1</i> measurable residual disease identifies high-risk patients, independent of transplantation in AML. <i>Blood Advances</i> , 2021, 5, 5258-5268.	5.2	12
8	Myeloproliferative Neoplasms (MPN) Clonal Evolution Landscape and Its Impact on Patients' Prognosis. <i>Blood</i> , 2021, 138, 317-317.	1.4	3
9	Retrospective Analysis of the Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin. <i>Blood</i> , 2021, 138, 876-876.	1.4	1
10	Genomic Landscape and Clinical Features of Myeloproliferative Neoplasm (MPN) Patients with Auto-Immune and Inflammatory Diseases (AID). <i>Blood</i> , 2021, 138, 1496-1496.	1.4	1
11	Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. <i>Blood Advances</i> , 2020, 4, 1942-1949.	5.2	49
12	Next-Generation Sequencing in Myeloid Neoplasm-Associated Sweet's Syndrome Demonstrates Clonal Relation between Malignant Cells and Skin-Infiltrating Neutrophils. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1873-1876.e5.	0.7	23
13	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. <i>Leukemia</i> , 2020, 34, 3149-3160.	7.2	54
14	Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1220-1225.	1.3	15
15	Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. <i>Leukemia</i> , 2020, 34, 1730-1740.	7.2	21
16	Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. <i>Blood</i> , 2020, 135, 542-546.	1.4	62
17	Molecular Characterization of Clinical Response and Relapse in Patients with <i>IDH1</i> -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine. <i>Blood</i> , 2020, 136, 49-51.	1.4	1
18	Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission. <i>Blood</i> , 2020, 136, 35-36.	1.4	16

#	ARTICLE	IF	CITATIONS
19	NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2020, 136, 36-36.	1.4	2
20	<i>SF3B1</i> mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2020, 136, 1-1.	1.4	4
21	Myeloid Blast Crisis of Philadelphia Positive Chronic Myeloid Leukemia and Philadelphia Positive Acute Myeloid Leukemia Treated at the AP-HP in Paris: A Retrospective Analysis. <i>Blood</i> , 2020, 136, 35-36.	1.4	0
22	Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 1856-1860.	7.2	7
23	Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. <i>Haematologica</i> , 2018, 103, 212-220.	3.5	62
24	Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. <i>Blood</i> , 2018, 132, 694-706.	1.4	132
25	Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial. <i>Blood</i> , 2018, 132, 993-993.	1.4	2
26	Outcomes Following Hematopoietic Stem Cell Transplantation in Patients Treated with Chemotherapy with or without Gemtuzumab Ozogamicin for Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 28-28.	1.4	5
27	Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02). <i>Blood</i> , 2018, 132, 31-31.	1.4	36
28	Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort. <i>Blood</i> , 2018, 132, 1428-1428.	1.4	1
29	Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort. <i>Blood</i> , 2018, 132, 4040-4040.	1.4	4
30	Intra-Tumor Heterogeneity in Acute Myeloid Leukemia (AML): Results from a Real Life Cohort. <i>Blood</i> , 2018, 132, 1537-1537.	1.4	0
31	Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database. <i>Blood</i> , 2018, 132, 3999-3999.	1.4	1
32	Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study. <i>Leukemia and Lymphoma</i> , 2017, 58, 586-593.	1.3	47
33	Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e184-e186.	3.5	6
34	Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2281-2288.	1.3	35
35	Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 3711-3719.	1.4	291
36	Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group. <i>Cancer</i> , 2015, 121, 2393-2399.	4.1	15

#	ARTICLE	IF	CITATIONS
37	Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, e196-e199.	3.5	16
38	Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma. <i>Annals of Hematology</i> , 2015, 94, 1859-1863.	1.8	4
39	Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study. <i>Haematologica</i> , 2015, 100, e128-e131.	3.5	26
40	Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2014, 38, 29-33.	0.8	16
41	Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials. <i>European Journal of Cancer</i> , 2014, 50, 1159-1168.	2.8	24
42	Evidence of Differentiation in Myeloid Malignancies Associated Neutrophilic Dermatitis: A Fluorescent In Situ Hybridization Study of 14 Patients. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1111-1114.	0.7	37
43	Identification Of Patients (pts) With Chronic Myeloid Leukemia (CML) At High Risk Of Artery Occlusive Events (AOE) During Treatment With The 2nd Generation Tyrosine Kinase Inhibitor (TKI) Nilotinib, Using Risk Stratification For Cardiovascular Diseases (CVD). <i>Blood</i> , 2013, 122, 2726-2726.	1.4	8
44	Oral Hydroxyurea Before Intensive Chemotherapy For Hyperleucocytic Acute Myeloid Leukemia Patients. <i>Blood</i> , 2013, 122, 2657-2657.	1.4	0
45	Epidemiology Of Invasive Aspergillosis (IA) During Induction Therapy In Adults With Acute Lymphoblastic Leukemia (ALL): A Graall-2005 Study. <i>Blood</i> , 2013, 122, 1394-1394.	1.4	0
46	Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APLâ€“ Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group. <i>Blood</i> , 2013, 122, 495-495.	1.4	0
47	A Phase I-II Study Of The Efficacy and Safety Of Lenalidomide (LEN) Combined To Azacitidine (AZA) In Higher Risk MDS and AML With Del 5q â€“ A Study By The Groupe Francophone Des Myelodysplasies (GFM). <i>Blood</i> , 2013, 122, 2750-2750.	1.4	2
48	Dose-Intensity Impacts On Survival of Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated in Adult Departments by a Pediatric Protocol (FRALLE 2000BT). <i>Blood</i> , 2012, 120, 3561-3561.	1.4	10
49	Final Report of GFM-VOR2007 Study: a Phase I/II Study of Vorinostat and Low Dose Cytarabine (LDAC) for MDS Patients with Azacitidine (AZA) Failure. <i>Blood</i> , 2012, 120, 3825-3825.	1.4	1
50	Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325). <i>Blood</i> , 2011, 118, 609-609.	1.4	8
51	Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent Cases, and Comparison with De Novo Cases. <i>Blood</i> , 2010, 116, 2171-2171.	1.4	0
52	Early Admission to the Intensive Care Unit In High Risk Acute Myeloid Leukemia Patients. <i>Blood</i> , 2010, 116, 4364-4364.	1.4	0
53	A Phase II Study of Postâ€“Remission Therapy with Azacitidine (AZA) in Patients with AML Post-MDS and High-Risk MDS: A GFM Group Study.. <i>Blood</i> , 2009, 114, 844-844.	1.4	29
54	Gut Aspergillus Infections in Leukemia and Stem Cell Transplant Patients: A Rare and Unrecognized Disease.. <i>Blood</i> , 2009, 114, 2220-2220.	1.4	5

#	ARTICLE	IF	CITATIONS
55	Fatigue and Daily Life in Patients with Essential Thrombocythemia: Comparisons Between the USA and France in 447 Patients.. Blood, 2009, 114, 2904-2904.	1.4	0
56	Intensive Consolidation with Clofarabine and Intermediate-Dose Cytarabine (CLARA) in Patients with High-Risk AML in First CR: The ALFA-0702 Pilot Study.. Blood, 2008, 112, 1934-1934.	1.4	1
57	Combined Treatment With Arsenic Trioxide and All-Trans-Retinoic Acid in Patients With Relapsed Acute Promyelocytic Leukemia. Journal of Clinical Oncology, 2003, 21, 2326-2334.	1.6	146